The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart–Lung Transplant Report—2016; Focus Theme: Primary Diagnostic Indications for Transplant

Abstract

and reported to the Registry. In addition to reporting key data for donor and recipient characteristics, transplant events and recipient treatments and outcomes, this year's report focuses on an overall theme of primary diagnostic indications for transplant. We present data on the distribution of diagnostic categories (see Figure 1), demographics of patients with the different lung disorders leading to the need for transplant, associations of the diagnoses with outcomes, and other data of interest related to this topic. The Registry's online slide sets show results from additional analyses and complementary information not included in this publication (see http:// ishlt.org/registries/slides.asp?slides=heartLungRegistry/). Data collection, conventions and statistical methods National and multinational organ/data exchange organizations and individual centers submit data to the ISHLT Registry. Since the Registry's inception, 457 heart transplant centers, 1,2 253 lung transplant centers 3 and 177 heart-lung transplant centers have reported data to the Registry. In our estimation, data submission to the Registry represents approximately two thirds of the worldwide thoracic transplant activity. This report presents an overview of donor and recipient characteristics and outcomes. Additional and extended analyses are presented in the aforementioned online slide sets (5 separate slide sets supplement the report data, including: "Introduction"; "Overall Lung Transplant"; "Overall Heart-Lung Transplant"; "Adult Lung Transplant"; and "Adult Heart-Lung Transplant"). The ISHLT website also contains slide sets for previous annual reports. This article refers to specific online eSlides when particular data are discussed but not presented due to space limitations; eSlide numbers refer to the online Adult Lung Transplant slides (e.g., eSlide LU 3) or Adult Heart-Lung Transplant slides (e.g., eSlide HL 3), unless otherwise specified. The Registry website also provides spreadsheets of the data elements collected in the Registry. Registry data quality depends on center reporting accuracy and completeness. The Registry uses various quality control measures to ensure acceptable data quality and completeness before including the data in the main data set and using the data for analyses. Analytical conventions Unless otherwise specified, analyses of lung transplants do not include heart-lung transplants. Retransplant includes those with a previously reported transplant of the same

Patient-reported health outcomes in long-term lung transplantation survivors: A prospective cohort study

“…More than 55 000 transplants have been performed worldwide over the last three decades. This quantitative increase was concurrent with improvements in the physical and mental aspects of health in these patients 1, 2. The survival rate has increased due to advances in surgical techniques and postoperative care such as guidance on lifestyle and administration of potent antimicrobial agents.…”

“…Lung transplantation, with a reported median survival of 5.8 years, is currently recognized as a worthwhile modality of treatment for patients with end‐stage lung diseases 1. More than 55 000 transplants have been performed worldwide over the last three decades.…”

Transplantology of the 21st century: High technologies in medicine and innovations in biomedical science

“…Появление новых лекарственных средств и инструментально-лабо-раторных методов, контролирующих состояние и функцию пересаженных органов, позволило до-биться высокого качества и значительной продол-жительности жизни пациентов после транспланта-ции легких (5-летняя выживаемость увеличилась до 70-80%), однако общая выживаемость реципиентов донорских легких все еще оставляет желать лучше-го в сравнении с выживаемостью реципиентов дру-гих органов [5].…”

Chronic lung allograft dysfunction phenotypes and treatment

“…Although improvement in surgical techniques and clinical expertise led to an improved in initial survival, long-term overall outcome remains poor. Graft failure and chronic lung allograft dysfunction (CLAD) are the major culprits for this inferior long-term outcome (2). CLAD has been introduced recently as an overarching term encompassing all forms of chronic (>3 weeks) pulmonary function decline.…”